Catenin (Cadherin-Associated Protein), Beta 1 (CTNNB1) genomic alterations are rare in prostate cancer (PCa), being found in ∼3–5% of the cases [1, 2]. This evidence concerns the gene CTNNB1 and posterior cortical atrophy.